Editas Medicine's ROIC is significantly lower than its WACC, indicating poor capital efficiency.Compared to peers, CRISPR Therapeutics shows the least negative ROIC to WACC ratio, suggesting better capital management.All companies in the gene editing space, including Beam Therapeutics and Pacific Biosciences, face challenges in generating returns above their cost of capital.Editas Medicine, Inc. (NASDAQ:EDIT) is a biotechnology company focused on developing gene editing technologies. The company aims to tra ...

De-extinction Project & Biodiversity - Biodiversity is projected to decrease by 27% in vertebrates by 2050 [1] - Colossal Laboratories and Biosciences claims to have brought back an extinct species of wolf, the direwolf [2] - Colossal aims to resurrect extinct species by generating organisms resembling and genetically similar to them, focusing on core genes [8] - Colossal plans to reintroduce woolly mammoths by 2028, along with projects involving the thylacine and dodo bird [15] Direwolf Project Details - Colossal used gene editing and cloning from ancient samples (13,000-year-old tooth and 72,000-year-old skull) to recreate direwolf pups [4] - Colossal identified 20 differences in 14 genes between grey wolf and direwolf genomes, accounting for distinguishing characteristics [5] - Direwolves existed from approximately 4 million years ago to 10,000 years ago, growing up to 178 cm and weighing 59-68 kg [9][10] - CRISPR technology was used to edit the genes, with five genes changed solely for the white coat characteristic [11][13] Species Definition & Project Validity - The definition of species involves interbreeding, while Colossal uses the morphological species concept (if they look like the animal, they are the animal) [6][7] - Greywolves are genetically more similar to jackals and African wild dogs than to direwolves [10] - Colossal currently has no plans for breeding the direwolves, which impacts the ability to determine if they can produce fertile offspring [14]